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Ovarian cancer is a leading cause of death in women, and despite primary 
treatment, the majority of patients relapse. As the cancer becomes chemoresistant, 
prognosis dramatically worsens. Metastasis, or the spread of cancer, is the primary cause 
of death in more than 90% of ovarian cancers. Taxol, a frontline chemotherapeutic drug, 
works by stabilizing microtubules, cytoskeletal filaments required for cell division. While 
it is known that microtubules affect cell adhesion, it remains unclear if chemoresistance 
alters cell adhesion to the extracellular environment. We tested this by isolating Taxol-
resistant cells, which displayed increased microtubule dynamics characterized by more 
rapid microtubule growth from fluorescently labeled EB3 microtubule protein. 
Additionally, they displayed faster adhesion rates and decreased adhesion strength, which 
could help overcome the rate-limiting step of metastasis. Adhesion strength was found to 
be independent of microtubule polymerization and dependent on up-regulated focal 
adhesion kinase (FAK) in the Taxol-resistant cells. Upon inhibition of FAK in these cells, 
microtubule dynamics decreased, signifying that adhesive signaling is up-stream of 
microtubule dynamics. Hence, by altering cell adhesion to the extracellular environment, 
Taxol-resistant cells show an increase in down-stream microtubule dynamics. This study 
consequently used FAK inhibition as a therapeutic target to improve prognosis by 








 Ovarian cancer, a leading cause of death in women, lacks effective, early 
detection techniques, resulting in more than 75% of the patients being diagnosed at an 
advanced stage of the disease.1 While improved surgical cancer removal methods and 
subsequent adjuvant platinum and taxane chemotherapy have increased progression-free 
survival, the disease remains largely incurable.2 Approximately 85% of patients relapse 
due to the genetic complexity and diversity of ovarian cancer cells; as cancer cells 
become chemoresistant, only 20% of ovarian cancers respond to the standard cocktail of 
drugs.1,3 Additionally, it is known that the majority of cancer-related deaths occur due to 
metastasis, the spread of cancer.  More importantly, the rate-limiting step of metastasis is 
adhesion at distant sites. The primary site of metastasis is the omentum, a soft tissue 
present inside the peritoneal cavity. However, the correlation between chemoresistance 
and metastasis remains largely unknown. 
The standard cocktail of drugs commonly consists of Taxol and Carboplatin. 
Taxol is known to alter microtubule dynamics of cancer cells thus potentially influencing 
the processes of cellular division, adhesion, and migration. Our lab previously showed 
that matrix stiffness induces changes in chemoresistance and adhesion.4 More 
specifically, we found that metastatic ovarian cancer cells preferentially bind to soft 
microenvironments and undergo morphological elongation characteristic of epithelial-
mesenchymal transition. Additionally, previous studies in our lab have elucidated various 
mechanisms by which Taxol resistance contributes to metastasis. Taxol-resistant SKOV3 
and OVCAR3 ovarian cancer cells display increased microtubule dynamics and weaker 
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adhesion to the extracellular matrix (ECM), which suggests that they more easily detach 
from the primary tumor sites compared to parent cancer cells. Staining for the focal 
adhesion proteins vinculin and paxillin, which are a part of intracellular complexes that 
serve as points of contact between the cell and the extracellular matrix, demonstrated that 
Taxol-resistant cells display smaller and fewer focal adhesions; the decrease in size and 
number of focal adhesions may contribute to the Taxol-resistant cells’ weaker adhesion. 
Moreover, we found Taxol-resistant cells to have increased cell motility and faster 
adhesion kinetics, helping them overcome the rate-limiting step of metastasis – adhesion 
at the soft omentum fat pads.  
We seek to target and block these characteristics of Taxol-resistant cells in order 
to not only regain sensitivity to Taxol, but to also prevent the essential steps of 
metastasis, such as detachment of tumor cells from the primary site and engraftment to 
distant sites. Previous studies have demonstrated that focal adhesion kinase (FAK), a 
cytoplasmic tyrosine kinase, promotes cell migration and increases focal adhesion 
turnover by contributing to the processes of actin remodeling and adhesion signaling.5 
Consequently, by specifically targeting FAK, we hope to find novel ways to overcome 





Ovarian cancer is a leading cause of death in women due to lack of effective, 
early detection techniques, with more than 75% of the patients presenting with an 
advanced stage of the disease during initial diagnosis.1,6 Although improved surgical 
cancer-debulking methods and subsequent adjuvant platinum and taxane based 
chemotherapy have increased progression-free survival, only 30% of patients with an 
advanced stage cancer have an overall survival period of 5 years.7 This high frequency of 
relapse despite successful primary treatment is largely observed due to the heterogeneity 
or genetic complexity of ovarian cancer cells.8 Moreover, with the majority of cancer-
related deaths occurring due to metastasis, or the spread of cancer from its primary tumor 
site to the metastatic site, there is an increased necessity for understanding the 
intracellular mechanism by which chemoresistance influences metastasis. 
Over the past fifty years, chemotherapeutics have evolved to best prevent cancer 
growth and metastasis after surgical removal. In the 1960s and early 1970s, alkylating 
agents like melphalan (Alkeran) and cyclophosphamide were administered singly with 
numerous prominent side effects. These drugs were replaced in the late 1970s and early 
1980s by various combinatorial mixes of doxorubicin, a topoisomerase inhibitor, 
cyclophosphamide, and cisplatin, a platinum-based therapeutic. Carboplatin, another 
platinum drug, progressively replaced cisplatin in the late 1980s due to its less toxic 
nature and fewer side effects.9 Furthermore, a prominent change occurred in the 1990s 
with the introduction of taxane drugs such as paclitaxel, which was shown to be 
increasingly effective against cancer reoccurrence when administered with 
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carboplatin.10,11 Recently, the use of carboplatin in conjunction with liposomal 
doxorubicin has been shown to demonstrate longer progression-free survival in recurrent 
ovarian cancer compared to carboplatin and paclitaxel chemotherapy.12 Nevertheless, 
carboplatin and paclitaxel continue to be more commonly used following surgery.7,13 
Paclitaxel in normal cancer cells is known to stabilize microtubules and 
consequently inhibit the regular processes of cellular division, adhesion, and migration. 
Understanding the variability in the binding of paclitaxel to various tubulin isotypes, after 
posttranslational modifications and mutations, is a potential primary target for 
understanding the mechanism of drug resistance. Previous research has demonstrated that 
higher expression of class III β tubulin plays a role in rendering resistance to paclitaxel 
because paclitaxel has preferential binding for class I β tubulin.14 Moreover, it is 
predicted that paclitaxel induces apoptosis by changing microtubule properties 
responsible for the release of proteins involved in the onset of apoptosis; activation of 
pro-apoptotic factors such as p53 and anti-apoptotic factors such as BCL2 are also 
tethered and/or transported by microtubules.15,16 However, further research has not 
demonstrated a direct dependence of paclitaxel on p53-regulated apoptosis, but the 
presence of functional p53 has been shown to enhance paclitaxel sensitivity in cancer 
cells.17 Similarly, research has not been able to directly link paclitaxel-induced apoptosis 
to the inactivation of BCL2, but there is evidence that overexpression of BCL2 confers 
inhibition of the downstream effect of paclitaxel on caspase-dependent apoptosis.18 
Moreover, mitotic arrest caused by paclitaxel may cause DNA damage that in turn 
activates p53 and inactivates BCL2.19,20 Although p53 has been shown to activate other 
pro-apoptotic proteins such as BCL2-Antagonist/Killer (BAK), there is still a need to 
 5 
further investigate the signaling pathways by which paclitaxel influences p53 and BCL2-
regulated apoptosis.21 
Carboplatin is another prominent drug used in the treatment of ovarian cancer, but 
its therapeutic mechanism differs from that of Paclitaxel. The hydrolyzed analog species 
of Carboplatin form an adduct with DNA strands through cross-linkage and induces DNA 
damage that recruits various repair proteins. These proteins consequently mediate an 
apoptotic response or cause cell cycle arrest.7 Recent research proposes that the active 
form of the tumor suppressor protein p14ARF leads to p53 inactivation via E3 ubiquitin 
ligase MDM2, conferring cells resistance to carboplatin; inhibition of p14ARF prevents 
p53 aggregation and allows the native form of p53 to be functional as an apoptosis 
inducer, reestablishing cell sensitivity to carboplatin.22 Thereafter, p53 perhaps leads to 
cell cycle arrest or apoptosis via mediating pro-apoptotic proteins such as BAK.  
Nevertheless, further investigation is still necessary to identify more feasible, potential 
targets for reestablishing sensitivity in chemoresistant ovarian cancer cells.  
While ovarian cancer research has commonly focused on drug-induced alteration 
of signaling pathways and consequent cell death, a new approach to understanding 
chemoresistance focuses on finding a connection between chemoresistance and cancer 
metastasis. For instance, the overexpression of AKT2, an anti-apoptotic protein, has been 
shown to up-regulate β1-integrin expression.23 Since the β-subunit of heterodimeric 
integrin membrane proteins plays an essential role in cellular adhesion to the extracellular 
matrix, increased expression confers more motility to the cells and increases their 
metastatic potential.24–26 Tumorigenesis is marked by several genetic alterations that 
produce oncogenes with dominant gain of function and tumor suppressor genes with 
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recessive loss of function. Therefore, it is optimal to find a drug that targets the invasive 
character of cancer cells and increases drug sensitivity. However, multiple pathways have 
been identified in increasing the invasiveness of cancer cells. The difficulty lies in 
identifying which pathway would be the most influential in reestablishing drug 
sensitivity; in part to the large number of cell cycle regulating proteins, it is also possible 
that multiple pathways may need to be targeted simultaneously to increase taxane 
sensitivity. 
As mentioned previously, integrins serve as receptors for ECM proteins and 
transduce biochemical signals that regulate processes such as cell proliferation, cell 
migration, and cell apoptosis. A critical mediator protein of integrin-based signaling is 
Focal Adhesion Kinase (FAK), a cytosolic tyrosine kinase co-localized with integrins in 
focal adhesions.26 Moreover, although the exact mechanism remains unclear, FAK has 
been shown to significantly interact with paxillin; while some studies propose paxillin to 
be a substrate of FAK, others demonstrate it to be simply a protein that anchors FAK to 
focal adhesion sites.26 Nevertheless, since FAK has been implicated in the promotion of 
cell migration and the prevention of cell apoptosis, it may be a promising target in 
reversing the effects of chemoresistance on both cellular adhesion strength and 
kinetics.27,28 This study will further investigate the mechanism by which chemoresistance 
affects the functionality of FAK by observing how the inhibition of FAK affects cell 
motility and adhesion in Taxol resistant cells of both the SKOV3 and OVCAR3 lineages. 
By targeting the adhesion and microtubule dynamics of Taxol resistant cells, the study 




MATERIALS AND METHODS 
A. Derivation of Taxol-resistant Cells 
Human ovarian carcinoma, SKOV-3 and OVCAR-3, cells were obtained from 
ATCC and Dr. John McDonald, respectively. Both cell lines were maintained in RPMI 
1640 (Corning) containing 10% FBS (Atlanta Biologicals) and 1% penicillin 
streptomycin (Corning). Cells of both lineages were selected for resistance to Taxol; they 
were plated at 20% of confluence and exposed to 10 nM Taxol (Enzo) for 48 hours 
before returning to growth media. After achieving 40% of confluence, cells were re-
exposed to 10 nM Taxol for 48 hours before returning to growth media. With the drug 
dose kept constant, the cells were treated until Taxol could no longer support cell growth, 
after which the cells were fed with standard growth media. Subsequently, 5 mM Taxol 
was added once per week since resistant cells require Taxol to maintain normal cell 
proliferation. Cell viability assays were performed to confirm no significant change in 
IC50 over the course of the study.  
B. Cell Viability Assay 
Cell viability was examined using a MTT assay. Initially, both SKOV3 and 
OVCAR3 cells were plated at 20% of confluence before exposing them to varying 
concentrations of Taxol, 25 µM Carboplatin, or DMSO (<0.1% v/v) as a solvent control. 
After 72 hours, the cells were incubated in 1mg/mL MTT reagent for four hours in 
standard growth conditions. Subsequently, the supernatant was replaced with isopropanol 
acidified with 4nM HCl, which solubilized the reduced formazan product. The 
absorbance was measured at 620 nm, with 595 nm as a reference value, using a DTX-800 
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Multimode Detector microwell plate reader (Beckman Coulter). Additionally, the IC50 
was determined by interpolating within the linear region since the data did not fit the 
traditional sigmoidal fit commonly associated with cell viability curves. 
C. Rhodamine Efflux Assay 
Rhodamine 123 was used as a model drug for the drug efflux assay. Studies were 
carried out in both the parent and Taxol-resistant populations of SKOV3 and OVCAR3 
cells. Cells were seeded in a 96-well plate, incubated with 0.5 µg/mL Rhodamine 123 for 
60 minutes, and then washed extensively with adhesion buffer. At various time points, 
the supernatant was removed; the green fluorescence of Rh 123 was excited at 485 nm 
and measured at an emission of 535 nm. The efflux was calculated as [Effluxed Rh 
123/(Effluxed Rh 123 + Rh 123 in cells)]. Efflux rate was determined using  [dCexternal/dt 
= kCinternal] where C is the concentration of Rhodamine 123 and k is the rate constant. A 
similar procedure was followed for 24-hour efflux, except the cells were incubated in 
growth media.  
D. Actin and Tubulin Stain 
Actin and tubulin proteins were visualized using immunofluorescence imaging. 
Parent and Taxol-resistant cells cultured on glass cover slips were extracted in a buffer 
containing 80 mM PIPES (pH 6.8), 1 mM MgCl2, 5 mM EDTA, and 0.5% Triton X-100 
before fixation with 0.5% glutaraldehyde in PBS. The reaction was subsequently 
quenched with 1 mg/mL sodium borohydride, permeabilized with Triton X-100, and 
blocked with FBS. Cells were stained for 1 hour at room temperature with 1:50 
Rhodamine Phalloidin rabbit-tubulin followed by 1:1000 goat anti-rabbit Alexa Flour 488 
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before sealing with Vectashield (Vector Labs) containing DAPI. Cells were visualized 
using either an inverted Nikon Eclipse Ti microscope.   
E. Microtubule Pelleting Assay 
The amount of polymerized and depolymerized tubulin in parent and Taxol-
resistant SKOV3 and OVCAR3 cells was quantified using a tubulin polymerization 
assay. Cells grown in the absence of Taxol for 5-7 days were grown to 80% of 
confluence in a 24-well plate. After lysing the cells with 100 µL of hypotonic lysis buffer 
(20 mM Tris-Hcl, pH 6.8, 0.5% Nonidet P-40, 1 mM MgCl2, 2 mM EGTA), they were 
transferred to a 1.5mL microcentrifuge tube. The wells were washed once with 100 µL of 
hypotonic lysis buffer, and the entire 200 µL volume was vortexed prior to pelleting out 
the insoluble fraction at room temperature centrifugation at 12,000 rcf for 10 minutes. 
The remaining cytoskeletal elements were dissolved in aforementioned buffer with 
addition of 0.5% SDS. The supernatants were transferred to different tube and the pellets 
were re-suspended in SDS-containing buffer with other insoluble tubulin proteins. 
Equivalent volumes of samples were loaded for the western blot procedure mentioned 
below.  
F. Western Blot Assay 
Parent and Taxol-resistant cells of both SKOV3 and OVCAR3 lineages were 
lysed using radioimmunoprecipitation buffer, which consisted of a mixture of protease 
inhibitors. The lysates were separated on either 10% (paxillin/tubulin) or 7.5% 
(vinculin/FAKp397) polyacrylamide gel before transferring to a PVDF membrane. These 
membranes were blocked in 5% milk, incubated overnight at 4°C in primary antibodies 
against tubulin (1:3000; Rockland), paxillin (1:500, BioLegend), vinculin (1:1000, 
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Invitrogen), or FAKp397 (1:1000, Genetex). The membranes were incubated with 1:1000 
HRP-conjugated anti-rabbit IgG (Rockland) and visualized using Novex ECL 
chemiluminescent substrate (Invitrogen). The total amount of protein was used as a 
loading control by staining the membranes with Coomassie G250 (BioRad). The protein 
bands were analyzed using blot analysis tools on ImageJ (NIH) as per the instructions in 
the user manual. 
G. Adhesion Strength Assay 
A centrifugal force-based study was used to assess adhesion strength. Both 
SKOV3 and OVCAR3 cells were allowed to adhere overnight to a collagen matrix in a 
96 well plate and labeled with Calcein AM. After replacing the media with adhesion 
buffer, an initial fluorescence reading was measured. The plate was centrifuged at 29 rcf 
for five minutes. After washing with adhesion buffer, a final fluorescence reading was 
taken. In order to calculate the attached fraction, the final fluorescence reading was 
divided by the initial fluorescence reading. Similar studies were performed with cells pre-
incubated with Taxol, Nocodazole (Sigma), or PF-228 (Sigma) for four hours.  
H. Focal Adhesion Stain 
Focal adhesions in parent and Taxol-resistant cells of both SKOV3 and OVCAR3 
lineages were visualized by staining paxillin and vinculin. Cells were also stained for 
focal adhesion kinase (FAK) to observe its expression. Cells were fixed using 4% 
formaldehyde, permeabilized with 0.5% Triton X-100, and blocked with 5% horse serum. 
Subsequently, they were stained with either 1:200 anti-paxillin (Clone Y113), 1:500 anti-
vinculin (Invitrogen), or 1:200 anti-FAKp397 (Genetex) diluted in PBS with 1% BSA. 
After washing, cells were incubated with 1:100 rhodamine phalloidin (Invitrogen) and 
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anti-rabbit Alexa Fluor 488 (Invitrogen), counterstained with DAPI (AnaSpec), and 
sealed with Vectashield on collagen I coated coverslips. The coverslips were imaged 
using an inverted Nikon Microscope at 40x with a CoolSNAP camera (Photometrics), 
and these images were normalized to the average for that session since light brightness 
may vary. Paxillin and vinculin images were used to quantify focal adhesions. The 
method utilized involved overlapping the images with a low pass Gaussian filter prior to 
the application of a morphological top hat filter. This procedure corrected for differences 
in basal paxillin and vinculin expression. Pixels that were above two standard deviations 
of the cell background, as determined based on F-actin fluorescence, were deemed 
positive. Noise less than 10 pixels (~0.25 µm2) were ignored, while the remaining 
segmented focal adhesion for analysis. The focal adhesion density was calculated as the 
integrated focal adhesion intensity normalized to cell area.  
I. Microtubule Tracking Assay using EB3 
Parent and Taxol-resistant cells of both SKOV3 and OVCAR3 lineages were 
transfected with mApple-EB3 (Addgene plasmid #54892), a fluorescently tagged protein, 
using the TransIT-LT1 transfection reagent (Mirus Bio). The live-cell microtubule 
dynamics were imaged with a Nikon Eclipse Ti inverted epifluorescent microscope, 
which was maintained at 37°C and 5% carbon dioxide using an In Vivo Scientific 
environmental cell chamber and Bioscience Tools CO2 controller. Imaging was 
performed using a Nikon CFI Apochromat TIRF 100X oil-immersion lens, while a 
Photometrics QuantEM CCD camera (Princeton Instruments) was used to minimize 
exposure time. Videos were capture at 1 Hz for two minutes and quantified using the 
open source u-track software.  
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J. Statistics 
Statistical analysis was performed using a student’s t-test or analysis of variance 
(ANOVA) followed by post-hoc analysis with Student-Newman-Keuls test; p < 0.05 was 
considered to be significant (*p<0.05, **p<0.01, ***p<0.001). Pearson correlation 
coefficients (ρ), ranging from -1 to +1 for perfectly inversely or positively correlated, 
respectively, were determined in MATLAB. All data are reported as mean ± standard 




















A. Drug Efflux and Other Pro-survival Adaptions do not Cause Taxol Resistance  
I. Establishing Taxol Resistance in SKOV3 and OVCAR3 Ovarian Cancer Cells 
In order to derive populations of SKOV3 and OVCAR3 ovarian cancer cells that 
were resistant to Taxol, parent populations were treated with Taxol and grown over time 
until Taxol could no longer support cell growth. We confirmed Taxol resistance by 
carrying out a cell viability assay, in which both the parent and Taxol-resistant cells were 
treated with Taxol at varying concentrations for 72 hours. The SKOV3 and OVCAR3 
parent populations displayed IC50 values of 2.3 ± 0.3 nM and 4.1 ± 1.8 nM, respectively, 
while the Taxol-resistant populations showed IC50 values of 22.1 ± 4.3 nM and 45.5 ± 4.9 
nM, respectively (Figure 1a). There was approximately a 10-fold increase in the IC50 for 
the Taxol-resistant populations, demonstrating that they show significantly increased 
viability at Taxol concentrations between 5-10 nM. At concentrations of Taxol larger 
than 10 nM, the viability of the Taxol-resistant populations decreased.  
II. Investigating Drug Efflux as a Mechanism of Chemoresistance 
A classical model of chemoresistance is drug efflux, in which the 
chemotherapeutic is pumped out of the cell at a higher rate than it is taken into the cell. In 
order to examine if the resistance to Taxol in the Taxol-resistant populations was a 
consequence of drug efflux, we evaluated the ability of cells to efflux Rhodamine 123. 
Rhodamine was used as a model drug since both Rhodamine 123 and Taxol use P-
glycoprotein as an efflux transporter.29 Drug efflux was observed over an initial two 
hours. The SKOV3 parent and Taxol-resistant populations showed rate constants of 0.73 
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± 0.09 h-1 and 0.72 ± 0.11 h-1, respectively, while the OVCAR3 parent and Taxol-
resistant populations showed rate constants of 0.70 ± 0.06 h-1 and 0.80 ± 0.13 h-1, 
respectively (Figure 1b). There was no significant difference in the efflux rate constants 
observed for the parental and Taxol-resistant populations of either the SKOV3 and 
OVCAR3 cell lines. 
III. Testing for Carboplatin Resistance 
In order to investigate the possibility of any inherent mechanisms of 
chemoresistance in both the SKOV3 and OVCAR3 cells, the respective parent and 
Taxol-resistant populations were treated with 25 µM of Carboplatin and tested for cell 
viability. As seen in Figure 1c, there was no significant difference in cell viability 
between the parent and Taxol-resistant populations, which suggests that the resistance 










































Figure 1. Derivation of Taxol-Resistant Cells and Analysis of Mechanisms of 
Chemoresistance. (A) Viability of Parent (-P) and Taxol-resistant (-T) populations of 
SKOV3 and OVCAR3 cells post incubation with varying concentrations of Taxol. Taxol-
resistant cells show a 10-fold increase in IC50. (B) Rhodamine Efflux over two hours used 
to calculate efflux rates (k), which showed no significant difference between the Parent (-
P) and Taxol-resistant (-T) populations. (C) Viability of Parent (-P) and Taxol-resistant (-
P) populations of SKOV3 and OVCAR3 cells post incubation with Carboplatin. There 
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B. Increased Microtubule Dynamics in Taxol-resistant Ovarian Cancer Cells 
I. Comparing Actin and Tubulin Expression in Parent and Taxol-resistant Populations 
Since Taxol is a microtubule-stabilizing drug, we examined cytoskeleton protein 
expression in parent and Taxol-resistant populations of SKOV3 and OVCAR3 cells. The 
Taxol-resistant cells appeared to have more depolymerized microtubules as observed by 
the less structured tubulin filaments from the immunofluorescent stain (Figure 2a). 
II. Comparing Tubulin Polymerization in Parent and Taxol-resistant Populations 
We sought to verify the microtubule dynamics seen from the immunofluorescent 
stain by comparing tubulin polymerization in the parental and Taxol-resistant populations 
of SKOV3 and OVCAR3 cells. The amount of tubulin was quantified using a 
microtubule-pelleting assay followed by western blot analysis. In the absence of Taxol, 
the SKOV3 Taxol-resistant population displayed less polymerized tubulin than its 
respective parent population (Figure 2b). However, upon treatment with 10 nM Taxol, 
the level of polymerized tubulin in the Taxol-resistant population increased to that of the 
parent population. Moreover, treatment with 100 nM Taxol increased tubulin 
polymerization to a level above that of the parent population. Similar results were 
obtained for the OVCAR3 cells, which indicates that Taxol-resistant cells have less 
tubulin polymerization than their parent cells. 
III. Comparing Microtubule Growth Rate and Growth Density in Parent and Taxol-
resistant Populations 
Microtubule dynamics were also characterized by comparing the microtubule 
growth rates in live parent and Taxol-resistant cells of SKOV3 and OVCAR3 lineages. 
Both cell populations were transfected with fluorescent end-binding protein (mApple-
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EB3), which binds to the growing end of the microtubules. Microtubule growth rates 
were quantified to be faster in the Taxol-resistant population of SKOV3 cells (Figure 2c). 
An increased number of microtubule growing plus ends was also observed in the same 
population (Figure 2d). Similar results were obtained for the OVCAR3 cells, which 
















































Figure 2. Taxol-resistant cells display increased microtubule dynamics. (A) Actin-
Tubulin Stain shows increased tubulin dynamics in Taxol-resistant cells of SKOV3 and 
OVCAR3 lineages. (B) Polymerized and soluble tubulin was separated using a 
microtubule pelleting assay and analyzed using Western Blot. Percent of polymerized 
tubulin was calculated by dividing polymerized tubulin by the sum of soluble and 
polymerized tubulin. SKOV3 Taxol-resistant cells displayed less polymerized tubulin 
than the parent cells, which was reversed with low doses of Taxol. (C-D) SKOV3 Taxol-
resistant cells show increased microtubule growth rate and density as determined by live-















































































C. Decreased Adhesion Strength in Taxol-resistant Cells due to Smaller and Fewer 
Focal Adhesion Formation 
I. Investigating Adhesion Strength in Parent and Taxol-resistant Populations 
Microtubule dynamics have been previously shown to influence adhesion 
signaling, which plays an essential role in processes such as cell migration, proliferation, 
and survival.30 Therefore, we compared the adhesion strength in the parent and Taxol-
resistant populations of SKOV3 and OVCAR3 cells using a centrifugal-force base 
adhesion assay. The cells were allowed to adhere overnight to a collagen-matrix prior to 
the application of centrifugal force. The adherent fractions of the Taxol-resistant 
populations were significantly less than that of their parent populations (Figure 3a). 
These results indicate that adherent fraction is inversely related to the IC50 values, 
suggesting that Taxol resistance confers weak adhesion to the ECM (Figure 3b).  
II. Examining Focal Adhesion Formation in Parent and Taxol-resistant Populations 
In order to further investigate the weak adhesion observed for the Taxol-resistant 
cells, we stained the parent and Taxol-resistant populations for focal adhesion protein 
paxillin. Both the SKOV3 and OVCAR3 parental populations displayed large focal 
adhesions throughout the cell periphery, while the Taxol-resistant populations featured 
smaller and fewer focal adhesions (Figure 3c). The focal adhesion density was calculated 
as the integrated density of segmented focal adhesions relative to the cell area (Figure 
3d). The total amount of paxillin was subsequently quantified using western blot analysis, 
which confirmed a significant decrease in the focal adhesion protein paxillin in both 
Taxol-resistant populations in comparison to their respective parent populations (Figure 
3e). While similar results were obtained for OVCAR3 cell populations when stained for 
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focal adhesion protein vinculin, neither of the SKOV3 populations displayed vinculin 
positive focal adhesions from the immunofluorescent stain (data not shown). However, 
western blot analysis was sensitive enough to measure differences in total vinculin, 
confirming a reduction of expression in both SKOV3 parent and Taxol-resistant 
populations. Taken together, these results suggest that decreased adhesion strength in the 




















































Figure 3. Taxol-resistant cells display weaker adhesion. (A) Centrifugal force-based 
adhesion strength assay showed that Taxol-resistant populations have a lower adherent 
fraction than parent populations. (B) The adherent fraction is inversely related to IC50 
values (p<0.01; ρ = -0.99). (C) Focal adhesion stain for paxillin revealed that Taxol-
resistant cells display smaller and fewer focal adhesions. (D) Focal adhesion density was 
quantified as the integrated density of segmented focal adhesions relative to cell area. (E) 
Total paxillin expression was quantified using Western blot and normalized to the total 
protein expression as determined from Coomassie stain. Taxol-resistant populations 
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D. Focal Adhesion Kinase Controls Adhesion Strength Which is Upstream of 
Microtubule Dynamics  
I. Examining a Relationship Between Adhesion Strength and Microtubule Dynamics 
Taxol-resistant cells of both SKOV3 and OVCAR3 lineages demonstrate 
increased microtubule dynamics and decreased adhesion strength. In order to determine 
the correlation between these two observed properties, we first hypothesized that 
alterations in microtubule dynamics were responsible for the decreased adhesion strength 
observed in the Taxol-resistant cells. We tested this relationship by treating the parent 
and Taxol-resistant populations of both SKOV3 and OVCAR3 cells with either Taxol or 
nocodazole to stabilize or depolymerize microtubules, respectively. We repeated the 
adhesion strength assay and realized no changes in the adhesive strength of either the 
parent or Taxol-resistant populations relative to the respective untreated controls (Figure 
4a-b). These results demonstrated that changes in adhesion strength were not directly 
related to microtubule dynamics.  
We subsequently hypothesized that the decreased focal adhesion formation was 
actually altering microtubule dynamics. We then examined the focal adhesion kinase 
(FAK) signaling pathway since the overexpression of FAK has been demonstrated in 
variety of invasive cancers.31 FAK phosphorylation was inhibited with PF228 (Figure 
4c), which has been shown to block focal adhesion turnover.32 After treating both the 
parent and Taxol-resistant populations with PF228, we repeated the adhesion strength 
assay. In parent cells, FAK inhibition showed no significant difference in the adherent 
fraction (Figure 4d). However, in the Taxol-resistant cells, FAK inhibition significantly 
increased the adherent fraction in comparison to the untreated control in a dose-
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dependent manner, reversing the effects of Taxol resistance on adhesion strength for all 
concentrations greater than 5 µM (Figure 4d). In order to confirm that alterations in 
adhesive strength were responsible for changes in microtubule dynamics, we repeated the 
microtubule plus-tip tracking with EB3 post FAK inhibition. It was observed that a 
significant (p<0.001) decrease in growth rate occurred for both the SKOV3 parent and 
Taxol-resistant cells (Figure 4e). More importantly, the growth rates of the parent and 
Taxol-resistant populations were comparable through a larger growth rate decrease in the 
Taxol-resistant cells. These results suggest that microtubule dynamics are down-stream 
of adhesive signaling and that changes in focal adhesion signaling cause alterations in 
microtubule dynamics causing an increase in resistance to microtubule-stabilizing drugs 





























Figure 4. FAK inhibition reverses changes in adhesion and microtubule dynamics. 
(A-B) SKOV3 parent and Taxol-resistant cells show no change in adherent fraction 
relative to their untreated controls (shaded regions) after 4 hours of treatment with 
varying concentrations of Taxol and Nocodazole. (C) FAK phosphorylation in parent and 
Taxol-resistant cells decreases upon treatment with PF228. (D) SKOV3 Taxol-resistant 
cells recover adhesive force after 4 hours of treatment with varying concentrations of 
PF228 until their adherent fraction becomes equivalent to that of the parent cells. (E) 
Live-cell imaging of microtubules with EB3 fluorescent tag post PF228 treatment. Parent 
and Taxol-resistant cells show significant decrease in growth rate until the values become 
















































A major factor attributed to chemoresistance in a variety of cancers is the lack of 
drug accumulation inside the cell.33 Previous research has demonstrated that P-
glycoprotein (Pgp) mediates this active efflux of chemotherapeutics from cancer cells. 
However, studies have also shown that not all chemoresistant cancer cells express Pgp; 
hence, other mechanisms must confer these cells resistance to chemotherapeutics. ABC 
transporters have also been identified in drug efflux, but inhibition of these proteins poses 
many clinical limitations.  
Taxol is a commonly used chemotherapeutic that targets microtubules and 
induces apoptosis by initiating mitotic arrest.34 Since its approval by the FDA in 1992, it 
has been increasingly used to treat many cancers.35 However, the development of 
resistance to the drug prevents the improvement of the overall response and survival of 
patients. Consequently, it is important to understand the mechanisms of Taxol resistance 
that arise from factors other than drug efflux and inherent, pro-survival adaptions. After 
establishing populations of SKOV3 and OVCAR3 Taxol-resistant cells (Figure 1a), we 
performed a Rhodamine 123 efflux assay to compare the drug accumulation levels in 
both the parent and Taxol-resistant populations; Rhodamine 123 was used as the model 
drug since both Rhodamine 123 and Taxol primary used P-glycoprotein as an efflux 
transporter. There was no significant difference observed in drug efflux between the 
parent and Taxol-resistant populations (Figure 1b), suggesting that drug efflux was not a 
dominant determinant of resistance. Furthermore, there was no significant change in cell 
viability observed between the parent and Taxol-resistant cells post Carboplatin treatment 
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(Figure 1c). These results led us to deduce that resistance to Taxol in the Taxol-resistant 
cells was arising due to some alternative mechanism. 
Consequently, we stained the parent and Taxol-resistant populations of both 
SKOV3 and OVCAR3 cells for cytoskeleton proteins and observed that the Taxol-
resistant cells appeared more dynamic (Figure 2a). The microtubules are not only 
growing at a faster rate in Taxol-resistant cells, but there is also a higher density of 
growing plus-ends (Figure 2c and 2d). Additionally, Taxol-resistant cells displayed less 
polymerized tubulin in the absence of drug (Figure 2b). However, when treated with low 
doses of Taxol, the level of polymerized tubulin became comparable to that of parent 
cells in controlled condition. These results explain the initial peak in viability seen for the 
Taxol-resistant cells under similar concentrations (Figure 1a). Hence, Taxol acts to 
stabilize the increased microtubule dynamics in the Taxol-resistant cells and allows these 
cells to properly divide and proliferate. 
Previously, it has been shown that microtubules stimulate the disassembly of focal 
adhesion through the use of focal adhesion kinase (FAK) and dynamin.36 Hence, we 
hypothesized that Taxol resistance was altering cellular adhesion. Using a centrifugal 
force-based assay, the adhesion strength of Taxol-resistant cells was determined to be 
lower than the parent cells (Figure 3a). Additionally, adhesion strength correlated 
strongly with Taxol sensitivity, as characterized by IC50 values (Figure 3b). The weaker 
adhesion observed in Taxol-resistant cells was further explained by the presence of 
smaller and fewer focal adhesions, as determined by and quantified from an 
immunofluorescence stain (Figure 3c and 3d). Western blot analysis confirmed that 
paxillin expression in the Taxol-resistant cells was indeed lower than in the parent cells 
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(Figure 3e). Thus, these results demonstrated that there is interplay between Taxol 
resistance and cellular adhesion, but the connection remains unclear.  
We further hypothesized that changes in microtubule dynamics were altering 
adhesion in the Taxol-resistant cells. The adhesion strength assay was repeated for both 
the parent and Taxol-resistant cells after treatment with either Taxol or Nocodazole, a 
microtubule-depolymerizing drug.37 However, there was no significant change in the 
adherent fraction between the parent or Taxol-resistant cells and their respective 
untreated controls after treatment with either drug (Figure 4a and 4b), signifying that an 
alternative microtubule-independent mechanism was conferring Taxol resistance.  
We subsequently examined if alterations in focal adhesions were causing changes 
in microtubule dynamics. In order to target the adhesion dynamics, we inhibited focal 
adhesion kinase (FAK), which is overexpressed in Taxol-resistant cells.5 Additionally, 
FAK silencing has been previously shown to increase sensitivity of ovarian cancer to 
taxanes.27  
After confirming that phosphorylation of FAK decreases post treatment with 
PF228 (Figure 4c), we repeated the adhesion strength assay and observed that the Taxol-
resistant cells recover adhesion strength comparable to the parent cells (Figure 4d), which 
confirms that FAK indeed plays a role in cellular adhesion. Subsequently, we repeated 
the microtubule plus-tip tracking study with fluorescent EB3 in order to observe any 
changes in microtubule growth rate post FAK inhibition. As previously shown, Taxol-
resistant cells displayed a higher microtubule growth rate than parent cells in the control 
group. However, after treatment with PF228, Taxol-resistant cells show a greater 
decrease in microtubule growth rate in comparison to the parent cells, until the rates are 
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relatively equal (Figure 4e). These results suggest that microtubule dynamics are 
downstream of adhesion signaling. More importantly, by targeting cellular adhesion in 
Taxol-resistant cells, we have demonstrated a method for Taxol-resistant cells to regain 
sensitivity to Taxol.  
In addition to overcoming chemoresistance, targeting adhesion dynamics may 
also reduce the progression of metastasis. The initial step of metastasis, which is 
detachment of cells from the primary tumor site, is aggravated due to the weaker 
adhesion observed in Taxol-resistant cells. Hence, by reversing the effects of resistance 
on adhesion strength via FAK inhibition, we may also be able to inhibit cell migration 
and invasion. Therefore, FAK not only provides a promising target for increasing 
chemosensitivity, but may also block metastasis and potentially improve the prognosis of 














Taxol-resistant ovarian cancer populations were confirmed to acquire resistance 
due to alternative mechanisms other than drug efflux and pro-survival adaptions. In 
comparison to the respective parent populations, SKOV3 and OVCAR3 Taxol-resistant 
cells displayed increased microtubule dynamics and weaker adhesion as a result of more 
depolymerized tubulin and smaller focal adhesions, respectively. Adhesion strength was 
found to be independent of microtubule polymerization and dependent on up-regulated 
focal adhesion kinase (FAK) in the Taxol-resistant cells. Furthermore, microtubule 
dynamics decreased post FAK inhibition, suggesting that microtubule dynamics are 
downstream of adhesion signaling. Since the inhibition of FAK reverses that changes 
seen in cell adhesion and microtubule dynamics in Taxol-resistant cells, it may be an 
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